While many prognostic signatures have been identified, all of them predict poor patient outcome either in luminal ER+ or in basal ER- tumors [10], thus requiring the context (microenvironment) of the particular tumor type to be predictive, they are agnostic of the existence of a common CSC population for luminal and basal breast cancer patients. This evidence concerns the gene ESR1 and neoplasm.